| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2702356 | Optometry - Journal of the American Optometric Association | 2010 | 4 Pages |
Abstract
Patients using MTX typically are monitored for adverse effects at scheduled intervals by their prescribing physician. Patients taking MTX and presenting with ischemic retinal findings warrant investigation for pancytopenia. Prompt workup and communication with the patient's prescribing doctor may be life-saving.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Stephanie O.D.,